Over the past 5 years, several new immunotherapy treatments have been tested for
metastatic renal cell carcinoma (mRCC). Clinical trials assessing combinations of different …

Introduction Significant advances have been made in the first-line therapy of metastatic renal
cell carcinoma (mRCC) since the approval of immune-based combinations, including …

Renal cell cancer (RCC) accounts for 3% of solid tumors worldwide, with an estimated
incidence of around 330.000 new cases per year. RCC is diagnosed in an advanced stage …

Background: In recent years, new therapeutic combinations based on immunotherapy
provided significant benefits as a first-line treatment for patients with advanced renal cell …

Immunotherapy (IO) with checkpoint inhibitors with or without anti-angiogenic tyrosine
kinase inhibitor (TKI)-based combinations have demonstrated superior efficacy over …

Simple Summary Recently, numerous treatments sharing similar mechanisms of action have
been approved for advanced renal cell carcinoma. These combinations prolong survival …

Purpose: Four recent first-line clinical trials leveraging immune-oncology agents
demonstrated an overall survival (OS) benefit relative to sunitinib. We aimed to provide …

Metastatic renal cell cancer (mRCC) management has undergone a paradigm shift in recent
decades. The first revolution came with the emergence of vascular endothelial growth factor …

Introduction Substantial paradigm shifts have been recently registered in metastatic renal
cell carcinoma (mRCC), with combination therapies including immunotherapy showing …

Purpose: Patient-reported outcomes (PRO) were evaluated in the phase III IMmotion151 trial
(NCT02420821) to inform overall treatment/disease burden of atezolizumab plus …